ArticlePloS one2026
Predictors of tuberculosis mortality among patients on treatment: A retrospective cohort study at a rural general hospital in Zambia.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite decades of global efforts and the availability of curative and preventive measures, tuberculosis (TB) continues to be the world's leading infectious disease cause of mortality, particularly in resource-limited settings. However, in developing countries, there is limited evidence on determinants of mortality during TB treatment, making it difficult to design targeted interventions. This study aimed to determine the incidence and factors associated with mortality among people diagnosed with TB at a rural health facility in Zambia.
methodsWe conducted a retrospective cohort study among 316 individuals who started TB treatment between May 2019 and March 2024. Participants were followed from treatment initiation until a treatment outcome was recorded, with a maximum follow-up time of 12 months. Demographic and clinical information were collected from medical records using a data collection tool via KoboTool software. The primary outcome was mortality. We used a multivariable Cox regression model to identify factors associated with TB mortality using Stata version 15.
resultsThe participants had a median age of 41 years (IQR: 32-54) and a median follow-up of 174 days (IQR: 155-191). Overall, 19.0% (n = 60; 95% CI: 14.8-23.8) of participants died, corresponding to an incidence rate of 42.1 per 100 person-years based on 51,968 person-days of follow-up (95% CI: 31.6-54.0). Age (adjusted hazard ratio (aHR): 1.017, 95% CI: 1.000-1.033, P = 0.042), clinically diagnosed TB had a significantly higher risk of mortality compared to those with bacteriologically confirmed TB (aHR: 1.97, 95% CI: 1.14-3.41, p = 0.015), and People living with HIV (aHR: 1.84, 95% CI: 1.03-3.29, P = 0.039) were significantly associated with increased mortality. While being on family-based directly observed therapy (DOT) (aHR: 0.42, 95% CI: 0.24-0.74, P = 0.003) and every unit increase in baseline weight (aHR: 0.96, 95% CI: 0.92-0.99, p = 0.004) was associated with a reduced risk of mortality.
conclusionThis study reveals a high incidence of TB-related mortality in a rural setting, which is significantly influenced by demographic and clinical determinants. The findings highlight the need for closer evaluation of patients with clinically diagnosed TB and strengthening family-based DOT as strategies to reduce mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.